56241-09-9

Basic information

• Product Name: 4-CHLORO-1(2H)-ISOQUINOLONE
• Synonyms: 4-CHLOROISOCARBOSTYRIL;4-CHLOROISOQUINOLIN-1(2H)-ONE;4-CHLORO-1(2H)-ISOQUINOLONE;4-CHLORO-1-HYDROXYISOQUINOLINE;4-Chloro-1-(2H)isoquinoline;4-Chloro-1(2H)-isoquinolinone;4-chloroisoquinolin-1-ol;4-Chloro-2H-isoquinolin-1-one
• CAS NO: 56241-09-9
• Molecular Formula: C₉H₆ClNO
• Molecular Weight: 179.6
• Mol File: 56241-09-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 235-237℃ (DEC)
• Boiling Point: 394.2 °C at 760 mmHg
• Flash Point: 192.2 °C
• Appearance: /
• Density: 1.38
• Vapor Pressure: 2.02E-06mmHg at 25°C
• Refractive Index: 1.641
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-CHLORO-1(2H)-ISOQUINOLONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-1(2H)-ISOQUINOLONE(56241-09-9)
• EPA Substance Registry System: 4-CHLORO-1(2H)-ISOQUINOLONE(56241-09-9)

Safety Data

• Hazardous Substances Data: 56241-09-9(Hazardous Substances Data)

Usage

General Description

4-Chloro-1(2H)-isoquinolone is a chemical compound with the molecular formula C9H6ClNO. It is a white to off-white crystalline solid that is insoluble in water but soluble in organic solvents. 4-Chloro-1(2H)-isoquinolone is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also utilized as a building block in organic synthesis and in the production of dyes and pigments. Additionally, 4-Chloro-1(2H)-isoquinolone has been found to have potential biological activity, with research indicating that it may have antibacterial and antifungal properties.

InChI:InChI=1/C9H6ClNO/c10-8-5-11-9(12)7-4-2-1-3-6(7)8/h1-5H,(H,11,12)

Upstream product

• 58022-38-1 4-chloro-1-methoxy-isoquinoline 
• 19493-44-8 1-chloroisoquinoline 
• 491-30-5 1-isoquinolone 
• 15298-58-5 1,4-dichloro-1,2-dihydrocyclobutisoquinoline 
• 7722-84-1 dihydrogen peroxide 
• 64-19-7 acetic acid 

Downstream Products

• 223671-81-6 4-chloro-1-oxo-1,2-dihydro-7-isoquinolinesulfonyl chloride 
• 256477-38-0 N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-N-(2-methoxybenzyl)glycine t-butyl ester 
• 256477-32-4 N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-N-(cyclohexylmethyl)-glycine t-butyl ester 
• 256477-41-5 N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-N-(3-chlorobenzyl)glycine t-butyl ester 
• 256477-42-6 N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-N-(4-methoxybenzyl)glycine t-butyl ester 
• 256477-40-4 N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-N-(3-methoxybenzyl)glycine t-butyl ester 
• 256478-24-7 N-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-N-(cyclohexylmethyl)glycine t-butyl ester 
• 739353-87-8 N-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-N-(4-methoxybenzyl)glycine t-butyl ester 

Relevant articles and documents

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

1-Isoquinolinylguanidines were previously disclosed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA). Further investigation of this template has revealed that incorporation of a 7-sulfonamide group furnishes a new series of potent and highly selective uPA inhibitors. Potency and selectivity can be achieved with sulfonamides derived from a variety of amines and is further enhanced by the incorporation of sulfonamides derived from amino acids. The binding mode of these 1-isoquinolinylguanidines has been investigated by X-ray cocrystallization studies. uPA inhibitor 26 was selected for further evaluation based on its excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). In vitro, compound 26 is able to inhibit exogenous uPA in human chronic wound fluid (IC50 = 0.89 μM). In vivo, in a porcine acute excisional wound model, following topical delivery, compound 26 is able to penetrate into pig wounds and inhibit exogenous uPA activity with no adverse effect on wound healing parameters. On the basis of this profile, compound 26 (UK-371,804) was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.

Composition for the treatment of damaged tissue

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.